Vero cell lines stably expressing HSV ICP0 protein
Provided herein are Vero cell lines that stably express Herpes Simplex Virus (HSV) ICP0 protein. These cells have the same morphology of Vero cells, exhibit stable expression of HSV ICP0 protein, and also efficiently complement replication of HSV ICP0 deficient virus for greater than 20, 30, or even 40 cell passages.
1. A Vero cell line comprising a nucleotide sequence that encodes for a Herpes Simplex virus (HSV) ICP0 protein operably linked to a promoter, wherein the promoter comprises SEQ ID NO: 2.
2. The Vero cell line of claim 1 , wherein the nucleotide sequence that encodes HSV-1 ICP0 encodes the amino acid sequence of SEQ ID NO: 5.
3. The Vero cell line of claim 1 , wherein, the cell line exhibits Vero cell morphology.
4. The Vero cell line of claim 1 , wherein the cell line is capable of maintaining ICP0 complementation efficiency within 2 standard deviations as measured by a viral replication assay for greater than 20 cell passages, 30 cell passages, or 40 cell passages.
5. The Vero cell line of claim 1 , wherein the cell line further comprises an additional nucleic acid that encodes a tetracycline repressor protein (tetR) operably linked to a promter.
6. The Vero cell line of claim 5 , wherein the promoter operably linked to the tetracycline repressor protein comprises SEQ ID NO: 9.
7. The Vero cell line of claim 5 , wherein the nucleic acid that encodes a tetracycline repressor protein has the sequence of SEQ ID NO: 11.
8. The Vero cell line of claim 5 , wherein the nucleic acid that encodes tetracycline repressor protein (tetR) operably linked to a promoter comprises or consists essentially of SEQ ID NO: 7.
9. The Vero cell line of claim 1 , further comprising a gene encoding antibiotic resistance.
10. The Vero cell line of claim 1 , further comprising an ICP0 deficient HSV virus.
11. The Vero cell line of claim 1 , further comprising a nucleic acid encoding a recombinant protein of interest that is operably linked to a promoter.
12. The Vero cell line of claim 11 , wherein the recombinant protein of interest is a therapeutic protein.
13. The Vero cell line of claim 12 , wherein the therapeutic protein is a vaccine protein.
14. The Vero cell line of claim 1 , wherein the nucleotide sequence comprises or consists essentially of the sequence of SEQ ID NO: 4.
15. A method of producing a viral vaccine of interest comprising propagating a virus to be used for vaccination in a Vero cell line of claim 1 .
16. The method of claim 15 , wherein the virus to be used for vaccination is an ICP0 deficient HSV virus.
17. The method of claim 15 , wherein the virus is an adenovirus.
18. A method of producing ICP0 deficient HSV virus comprising i) infecting a Vero cell line of claim 1 , with an ICP0 deficient HSV virus, ii) incubating the cell line in a tissue culture medium; and iii) collecting the ICP0 deficient virus produced by the cell line.